

Exceptions Criteria

bictegravir/lenacapavir (BIC/LEN)

New to Market Block (NTMB)

This document informs prescribers of formulary alternatives and provides an exception process for non-formulary products through prior authorization.

Plan Design Summary

This program applies to non-formulary medications. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the formulary alternatives and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Fixed-Dose Combination Antiretroviral Products for Human Immunodeficiency Virus (HIV)

Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

Formulary	Preferred Formulary Alternatives
Standard Control Choice Formulary (SCCF)	Biktarvy, Cabenuva, Dovato, efavirenz-emtricitabine-tenofovir disoproxil fumarate, efavirenz-lamivudine-tenofovir disoproxil fumarate, emtricitabine-rilpivirine-tenofovir disoproxil fumarate, Genvoya, Odefsey, Symtuza, Triumeq
Standard Control Formulary (SF)	Biktarvy, Cabenuva, Dovato, efavirenz-emtricitabine-tenofovir disoproxil fumarate,

	efavirenz-lamivudine-tenofovir disoproxil fumarate, emtricitabine-rilpivirine-tenofovir disoproxil fumarate, Genvoya, Odefsey, Symtuza, Triumeq
Advanced Control Specialty Choice Formulary (ACSCF)	Biktarvy, Cabenuva, Dovato, efavirenz-emtricitabine-tenofovir disoproxil fumarate, efavirenz-lamivudine-tenofovir disoproxil fumarate, emtricitabine-rilpivirine-tenofovir disoproxil fumarate, Genvoya, Odefsey, Symtuza, Triumeq
Advanced Control Specialty Formulary (ACSF)	Biktarvy, Cabenuva, Dovato, efavirenz-emtricitabine-tenofovir disoproxil fumarate, efavirenz-lamivudine-tenofovir disoproxil fumarate, emtricitabine-rilpivirine-tenofovir disoproxil fumarate, Genvoya, Odefsey, Symtuza, Triumeq
Value Formulary (VF)	Biktarvy, Cabenuva, Dovato, efavirenz-emtricitabine-tenofovir disoproxil fumarate, efavirenz-lamivudine-tenofovir disoproxil fumarate, emtricitabine-rilpivirine-tenofovir disoproxil fumarate, Genvoya, Juluca, Odefsey, Symtuza, Triumeq
Standard Formulary Chart (SFC)	Biktarvy, Delstrigo, Dovato, efavirenz-emtricitabine-tenofovir disoproxil fumarate, efavirenz-lamivudine-tenofovir disoproxil fumarate, emtricitabine-rilpivirine-tenofovir disoproxil fumarate, Genvoya, Odefsey, Symtuza
Advanced Control Specialty Formulary Chart (ACSFC)	Biktarvy, Delstrigo, Dovato, efavirenz-emtricitabine-tenofovir disoproxil fumarate, efavirenz-lamivudine-tenofovir disoproxil fumarate, emtricitabine-rilpivirine-tenofovir disoproxil fumarate, Genvoya, Odefsey, Symtuza
Value Formulary Chart (VFC)	Biktarvy, Cabenuva, Delstrigo, Dovato, efavirenz-emtricitabine-tenofovir disoproxil fumarate, efavirenz-lamivudine-tenofovir disoproxil fumarate, emtricitabine-rilpivirine-tenofovir disoproxil fumarate, Genvoya, Juluca, Odefsey, Symtuza, Triumeq

Reference number(s)
7560-D

Exception Criteria

Coverage for bictegravir/lenacapavir (BIC/LEN) for human immunodeficiency virus (HIV) treatment is provided when the member has a documented historical resistance, intolerable adverse event, or contraindication to all of the preferred formulary alternatives or active ingredients within all of the preferred formulary alternatives.